Advanz Pharma

Industry · 10 registered clinical trials.

Status	Trial	Phase	Started
Completed	Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases Renal Insufficiency, Hepatic Insufficiency, Immunosuppression	—	2020-03-30
Withdrawn	A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrill Atrial Fibrillation	Phase 4	2012-09-01
Completed	A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation Atrial Fibrillation	Phase 3	2010-08-01
Terminated	A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(M Atrial Fibrillation	Phase 3	2009-10-01
Completed	A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation Atrial Fibrillation	Phase 3	2008-04-01
Completed	Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study Atrial Fibrillation	Phase 2	2007-03-01
Completed	Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence Atrial Fibrillation	Phase 2	2005-12-01
Completed	Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation Atrial Fibrillation	Phase 3	2003-08-01
Completed	A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter Atrial Flutter	Phase 2 / Phase 3	2003-08-01
Completed	Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure Congestive Heart Failure	Phase 2 / Phase 3	2003-03-01